GB201106743D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201106743D0
GB201106743D0 GB201106743A GB201106743A GB201106743D0 GB 201106743 D0 GB201106743 D0 GB 201106743D0 GB 201106743 A GB201106743 A GB 201106743A GB 201106743 A GB201106743 A GB 201106743A GB 201106743 D0 GB201106743 D0 GB 201106743D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
compounds
therapy
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201106743A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to GB201106743A priority Critical patent/GB201106743D0/en
Publication of GB201106743D0 publication Critical patent/GB201106743D0/en
Priority to BR112013026834A priority patent/BR112013026834A2/pt
Priority to CA2832763A priority patent/CA2832763C/en
Priority to EP12716378.0A priority patent/EP2699550B1/en
Priority to PCT/EP2012/057111 priority patent/WO2012143413A1/en
Priority to AU2012244759A priority patent/AU2012244759B2/en
Priority to CN201280029939.XA priority patent/CN103619820B/zh
Priority to MX2013012190A priority patent/MX338515B/es
Priority to KR1020137030972A priority patent/KR101896599B1/ko
Priority to US14/111,580 priority patent/US9029395B2/en
Priority to EA201391285A priority patent/EA022341B1/ru
Priority to ES12716378.0T priority patent/ES2544302T3/es
Priority to JP2014505610A priority patent/JP5840763B2/ja
Priority to SG2013076146A priority patent/SG194469A1/en
Priority to IL228707A priority patent/IL228707A/en
Priority to ZA2013/07645A priority patent/ZA201307645B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB201106743A 2011-04-21 2011-04-21 Novel compounds Ceased GB201106743D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GB201106743A GB201106743D0 (en) 2011-04-21 2011-04-21 Novel compounds
SG2013076146A SG194469A1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
CN201280029939.XA CN103619820B (zh) 2011-04-21 2012-04-19 可用作溴区结构域抑制剂的四氢喹啉衍生物
KR1020137030972A KR101896599B1 (ko) 2011-04-21 2012-04-19 브로모도메인 억제제로서 유용한 테트라하이드로퀴놀린 유도체
EP12716378.0A EP2699550B1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
PCT/EP2012/057111 WO2012143413A1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
AU2012244759A AU2012244759B2 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
BR112013026834A BR112013026834A2 (pt) 2011-04-21 2012-04-19 composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
MX2013012190A MX338515B (es) 2011-04-21 2012-04-19 Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
CA2832763A CA2832763C (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
US14/111,580 US9029395B2 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors
EA201391285A EA022341B1 (ru) 2011-04-21 2012-04-19 Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
ES12716378.0T ES2544302T3 (es) 2011-04-21 2012-04-19 Derivados de tetrahidroquinolina útiles como inhibidores de bromodominio
JP2014505610A JP5840763B2 (ja) 2011-04-21 2012-04-19 ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体
IL228707A IL228707A (en) 2011-04-21 2013-10-03 Tetrahydroquinoline history used as bromodomain inhibitors
ZA2013/07645A ZA201307645B (en) 2011-04-21 2013-10-14 Tetrahydroquinoline derivatives useful as bromodomain inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201106743A GB201106743D0 (en) 2011-04-21 2011-04-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB201106743D0 true GB201106743D0 (en) 2011-06-01

Family

ID=44147335

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201106743A Ceased GB201106743D0 (en) 2011-04-21 2011-04-21 Novel compounds

Country Status (16)

Country Link
US (1) US9029395B2 (cg-RX-API-DMAC7.html)
EP (1) EP2699550B1 (cg-RX-API-DMAC7.html)
JP (1) JP5840763B2 (cg-RX-API-DMAC7.html)
KR (1) KR101896599B1 (cg-RX-API-DMAC7.html)
CN (1) CN103619820B (cg-RX-API-DMAC7.html)
AU (1) AU2012244759B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013026834A2 (cg-RX-API-DMAC7.html)
CA (1) CA2832763C (cg-RX-API-DMAC7.html)
EA (1) EA022341B1 (cg-RX-API-DMAC7.html)
ES (1) ES2544302T3 (cg-RX-API-DMAC7.html)
GB (1) GB201106743D0 (cg-RX-API-DMAC7.html)
IL (1) IL228707A (cg-RX-API-DMAC7.html)
MX (1) MX338515B (cg-RX-API-DMAC7.html)
SG (1) SG194469A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012143413A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307645B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CN105189461B (zh) * 2013-03-14 2018-05-15 葛兰素史克知识产权第二有限公司 2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途
EA035469B1 (ru) 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
SG10201900631TA (en) 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
WO2016038120A1 (en) 2014-09-12 2016-03-17 Glaxosmithkline Intellectual Property (No.2) Limited Tetrahydroquinoline derivatives as bromodomain inhibitors
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
KR20170055549A (ko) * 2014-10-02 2017-05-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 화합물
HK1245246A1 (zh) 2014-12-01 2018-08-24 恒翼生物医药科技(上海)有限公司 作为溴域抑制剂的取代吡啶酮
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
EP3490552B1 (en) 2016-07-26 2022-11-23 University of Southern California Selective bromodomain inhibition of fungal bdf1
US11028051B2 (en) * 2016-12-13 2021-06-08 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
WO2010113498A1 (ja) * 2009-03-31 2010-10-07 興和株式会社 テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
GB0919431D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011054851A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013033268A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same

Also Published As

Publication number Publication date
JP5840763B2 (ja) 2016-01-06
WO2012143413A1 (en) 2012-10-26
IL228707A (en) 2016-09-29
US9029395B2 (en) 2015-05-12
US20140039006A1 (en) 2014-02-06
AU2012244759B2 (en) 2016-03-03
KR20140025484A (ko) 2014-03-04
CA2832763C (en) 2019-09-24
JP2014511891A (ja) 2014-05-19
ZA201307645B (en) 2015-04-29
IL228707A0 (en) 2013-12-31
MX338515B (es) 2016-04-20
ES2544302T3 (es) 2015-08-28
EA022341B1 (ru) 2015-12-30
KR101896599B1 (ko) 2018-09-07
AU2012244759A1 (en) 2013-10-31
EP2699550B1 (en) 2015-06-10
EA201391285A1 (ru) 2014-04-30
EP2699550A1 (en) 2014-02-26
MX2013012190A (es) 2014-01-31
BR112013026834A2 (pt) 2016-12-27
CN103619820A (zh) 2014-03-05
CN103619820B (zh) 2015-08-19
SG194469A1 (en) 2013-12-30
CA2832763A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
GB201106750D0 (en) Novel compounds
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
GEP20186816B (en) Anty il-36r antybodies
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
IN2014CN00568A (cg-RX-API-DMAC7.html)
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
IN2014MN02598A (cg-RX-API-DMAC7.html)
IL237839A0 (en) History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them
MX349004B (es) Nuevos compuestos.
IN2014DN06104A (cg-RX-API-DMAC7.html)
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
IL235414A (en) The history of pyrolotriazinone, their preparation and their pharmaceutical preparations
PH12015501609A1 (en) Phenicol antibacterials
IL232577A (en) History of morpholinylbenzotriazine, their preparation and their pharmaceutical preparations
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
ZA201400646B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
IL230219A0 (en) History of dihydropyrazole, their preparation and pharmaceutical preparations containing them
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IL238826A (en) History of imidazole - piperidinyl, their preparation and their pharmaceutical preparations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)